bioRxiv Science⌕ Search

Biology subjects

Fadelu, T.

Publications and source records attributed to Fadelu, T..

2 recordsLinked to original sources

A Common Pathogenic Founder Variant in Rwandan Breast Cancer Cases

Germline data from African populations remain sparse, limiting characterization of population-specific BRCA1/2 pathogenic variants. In a study of 175 Rwandan women with breast cancer, 7 unrelated carriers (4% of cases; 22% of pathogenic variant carriers) harbored the same BRCA1 frameshift variant, c.4065_4068del (p.Asn1355Lysfs*10), which is extremely rare in gnomAD yet recurrent in European, Asian, and Middle Eastern cohorts. Whole-exome sequencing and haplotype analysis of all 7 carriers revealed a shared ancestral block of approximately 581 kb surrounding the variant, and extended haplotype homozygosity and network analyses confirmed a common founder origin. Coalescent-based age estimation placed the founder event approximately 4,000--10,000 years ago. Comparison with 1000 Genomes Project data showed the founder haplotype is absent or exceedingly rare outside African and South Asian populations. These findings strongly suggest the c.4065_4068del variant as a pre-historical BRCA1 founder variant in Rwanda, with implications for targeted genetic testing, cascade screening, and cancer prevention in the region.

genetics↗

ESPWA: a deep learning-enabled tool for precision-based use of endocrine therapy in resource-limited settings

Immunohistochemistry for estrogen receptor (ER) expression is often unavailable in low-and-middle-income countries (LMICs), leading to empiric use of endocrine therapy (ET) and unnecessary toxicity in ER-negative patients. To address this unmet need, we developed ESPWA, a deep-learning model trained on 3448 H&E slides and tissue-matched ER status from breast cancer patients treated at Zanmi Lasante (ZL), Haiti. A model trained on The Cancer Genome Atlas (TCGA) exhibited substantial domain shift when applied to the ZL cohort, with AUROCs dropping from 0.846 on TCGA cross-validation to 0.671 on the ZL cohort. In contrast, ESPWA demonstrated improved performance on ZL cross-validation (AUROC=0.790; p=0.005). In an independent test set of 134 Haitian patients with parallel slides prepared and scanned in Mirebalais Hospital (Haiti) and Brigham and Womens Hospital, ESPWA was robust to variations in slide preparation, quality, and scanners, achieving AUROCs of 0.794 on BWH-prepared WSIs and 0.805 on Mirebalais-prepared WSIs. Prospective studies using ESPWA are underway in sub-Saharan Africa to evaluate its utility in informing precision-based use of ET.

cancer biology↗